



PRESS RELEASE DECEMBER 3<sup>rd</sup>, 2010

## MOBERG DERMA SIGNS DISTRIBUTION AGREEMENT IN SWITZERLAND

**Moberg Derma AB (publ.) has entered into a distribution agreement with Gebro Pharma AG S.A. for Emtrix<sup>®</sup> – for treatment of discolored and deformed nails resulting from fungal infection (onychomycosis) or psoriasis, and Kaprolac<sup>®</sup> – for problems with dry and flaky skin and. Under the agreement, Gebro is granted exclusive rights to market and sell Emtrix<sup>®</sup>, Kaprolac<sup>®</sup> Dandruff Shampoo and Kaprolac<sup>®</sup> Scalp Solution in Switzerland and the Principality of Lichtenstein.**

*"The agreement with Gebro follows on a positive response in the Nordic market since the launch in September. Our Nordic distributor has already placed orders amounting to three times the forecasted volumes for the first twelve months. The total sales to our distributors now exceeds 200 000 units",* comments Moberg Derma's CEO, Peter Wolpert.

### **About Emtrix<sup>®</sup> and nail diseases**

Emtrix<sup>®</sup> is a prescription free, topical nail product and has the potential to become first-line treatment for common nail disorders. Launch of Emtrix<sup>®</sup> was initiated in the first markets in September 2010. Safety and efficacy has been demonstrated in several clinical studies including more than 500 patients. Emtrix<sup>®</sup> has a unique and rapid mechanism of action which brings visible improvements within 2-4 weeks of treatment.

Nail fungus is the most common nail disease and afflicts approximately 10% of the general population and is more common in the elderly. The estimated global market potential exceeds USD 1 billion. The untapped potential is significant since many patients remain untreated. It is generally recognized that there is a need for new efficacious and safe topical treatments.

### **About Kaprolac<sup>®</sup> and dry and scaly skin**

The Kaprolac<sup>®</sup> product range includes five environmentally friendly, non-prescription products, the first of which were launched in autumn 2010. Efficacy and safety have been demonstrated in several clinical trials on over 400 patients. Kaprolac<sup>®</sup> has clinically proven emollient and keratolytic effects and is based on proven compounds with documented safety. The products are based on biodegradable substances, are free from preservatives and have been granted the Nordic ecolabel - 'Svanen'.

Dry skin is a common problem - not least for patients with atopic eczema. The prevalence of atopic eczema in developed countries is 15-30% in children and 2-10% in adults.

### **For further information, please contact:**

Peter Wolpert, President and CEO of Moberg Derma  
Telephone: +46 8 522 307 00  
Mobile: +46 735 71 35  
E-mail: [peter.wolpert@mobergderma.se](mailto:peter.wolpert@mobergderma.se)

### **About Moberg Derma**

Moberg Derma AB (publ.), based in Stockholm, develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery. The company's products are based on proven compounds, which reduce time to market, development costs and risk. The portfolio covers projects in the preclinical phase to approved and launched products. The company began operations at the Karolinska Institute in Stockholm in 2006. Moberg Derma is owned by institutional and private investors, Board and management. For further information, please visit:

[www.mobergderma.se](http://www.mobergderma.se)